410 related articles for article (PubMed ID: 35273607)
1. Polymeric Systems for Cancer Immunotherapy: A Review.
Le TMD; Yoon AR; Thambi T; Yun CO
Front Immunol; 2022; 13():826876. PubMed ID: 35273607
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors.
Porter CE; Rosewell Shaw A; Jung Y; Yip T; Castro PD; Sandulache VC; Sikora A; Gottschalk S; Ittman MM; Brenner MK; Suzuki M
Mol Ther; 2020 May; 28(5):1251-1262. PubMed ID: 32145203
[TBL] [Abstract][Full Text] [Related]
3. Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment.
Shi T; Song X; Wang Y; Liu F; Wei J
Front Immunol; 2020; 11():683. PubMed ID: 32411132
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment.
Rosewell Shaw A; Suzuki M
Front Immunol; 2018; 9():2103. PubMed ID: 30298067
[TBL] [Abstract][Full Text] [Related]
5. Combinatorial Approaches for Cancer Treatment Using Oncolytic Viruses: Projecting the Perspectives through Clinical Trials Outcomes.
Malogolovkin A; Gasanov N; Egorov A; Weener M; Ivanov R; Karabelsky A
Viruses; 2021 Jun; 13(7):. PubMed ID: 34209981
[TBL] [Abstract][Full Text] [Related]
6. Combining Oncolytic Viruses with Chimeric Antigen Receptor T Cell Therapy.
McGrath K; Dotti G
Hum Gene Ther; 2021 Feb; 32(3-4):150-157. PubMed ID: 33349123
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral Immunotherapy-Update 2019.
Hamid O; Ismail R; Puzanov I
Oncologist; 2020 Mar; 25(3):e423-e438. PubMed ID: 32162802
[TBL] [Abstract][Full Text] [Related]
8. Development of oncolytic virotherapy: from genetic modification to combination therapy.
Lan Q; Xia S; Wang Q; Xu W; Huang H; Jiang S; Lu L
Front Med; 2020 Apr; 14(2):160-184. PubMed ID: 32146606
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic viruses for cancer immunotherapy.
Hemminki O; Dos Santos JM; Hemminki A
J Hematol Oncol; 2020 Jun; 13(1):84. PubMed ID: 32600470
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors.
Medikonda R; Pant A; Lim M
Adv Exp Med Biol; 2023; 1394():73-84. PubMed ID: 36587382
[TBL] [Abstract][Full Text] [Related]
11. Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager.
Wing A; Fajardo CA; Posey AD; Shaw C; Da T; Young RM; Alemany R; June CH; Guedan S
Cancer Immunol Res; 2018 May; 6(5):605-616. PubMed ID: 29588319
[TBL] [Abstract][Full Text] [Related]
12. IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy.
Chen T; Ding X; Liao Q; Gao N; Chen Y; Zhao C; Zhang X; Xu J
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33504576
[TBL] [Abstract][Full Text] [Related]
13. Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids.
Hamdan F; Ylösmäki E; Chiaro J; Giannoula Y; Long M; Fusciello M; Feola S; Martins B; Feodoroff M; Antignani G; Russo S; Kari O; Lee M; Järvinen P; Nisen H; Kreutzman A; Leusen J; Mustjoki S; McWilliams TG; Grönholm M; Cerullo V
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34362830
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic viruses as a promising therapeutic strategy for hematological malignancies.
Yang C; Hua N; Xie S; Wu Y; Zhu L; Wang S; Tong X
Biomed Pharmacother; 2021 Jul; 139():111573. PubMed ID: 33894623
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic adeno-immunotherapy modulates the immune system enabling CAR T-cells to cure pancreatic tumors.
Rosewell Shaw A; Porter CE; Yip T; Mah WC; McKenna MK; Dysthe M; Jung Y; Parihar R; Brenner MK; Suzuki M
Commun Biol; 2021 Mar; 4(1):368. PubMed ID: 33742099
[TBL] [Abstract][Full Text] [Related]
16. Overview of the pre-clinical and clinical studies about the use of CAR-T cell therapy of cancer combined with oncolytic viruses.
Zarezadeh Mehrabadi A; Roozbahani F; Ranjbar R; Farzanehpour M; Shahriary A; Dorostkar R; Esmaeili Gouvarchin Ghaleh H
World J Surg Oncol; 2022 Jan; 20(1):16. PubMed ID: 35027068
[TBL] [Abstract][Full Text] [Related]
17. Chimeric antigen receptor T cell therapy and other therapeutics for malignancies: Combination and opportunity.
Wang L; Yao R; Zhang L; Fan C; Ma L; Liu J
Int Immunopharmacol; 2019 May; 70():498-503. PubMed ID: 30875561
[TBL] [Abstract][Full Text] [Related]
18. Surface engineering of oncolytic adenovirus for a combination of immune checkpoint blockade and virotherapy.
Lv P; Chen X; Fu S; Ren E; Liu C; Liu X; Jiang L; Zeng Y; Wang X; Liu G
Biomater Sci; 2021 Nov; 9(22):7392-7401. PubMed ID: 34751685
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic potential of CAR T cell in malignancies: A scoping review.
Mehrabadi AZ; Ranjbar R; Farzanehpour M; Shahriary A; Dorostkar R; Hamidinejad MA; Ghaleh HEG
Biomed Pharmacother; 2022 Feb; 146():112512. PubMed ID: 34894519
[TBL] [Abstract][Full Text] [Related]
20. Advances in immunotherapy for glioblastoma multiforme.
Mahmoud AB; Ajina R; Aref S; Darwish M; Alsayb M; Taher M; AlSharif SA; Hashem AM; Alkayyal AA
Front Immunol; 2022; 13():944452. PubMed ID: 36311781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]